期刊文献+

氨来呫诺口含片的处方优化和质量标准研究 被引量:4

Optimization of Formulation and Quality Standards of Amlexanox Buccal Tablets
下载PDF
导出
摘要 目的:优化氨来呫诺口含片的处方工艺,并建立氨来呫诺口含片的质量标准。方法:以卡波姆和羟丙甲基纤维素的总量在处方中所占的比例(因素A)和卡波姆与羟丙甲基纤维素的重量比(因素B)为考察因素,以颗粒的流动性和溶化性作为考察指标,采用正交试验设计法优化处方,采用高效液相色谱法测定氨来呫诺含量。结果:最佳处方为卡波姆和羟丙甲基纤维素的总量在处方中占60%,卡波姆与羟丙甲基纤维素的重量比为1:3。制得的氨来呫诺含片口感好、表面光滑美观、色泽均匀、硬度适中、服用方便,质量可靠。结论:氨来呫诺含片制剂处方工艺简单合理,质量可控。 Objective: To optimize the formulation and establish quality standards of amlexanox buccal tablets. Method: The formula was optimized by orthogonal design using the weight percentage of Carbopol and HPMC (factor A) and the weight ratio of Carbopol and HPMC ( factor B) as the factors, and dissolubility and fluidity of the granules as the indices. The content of amlexanox was determined by HPLC. Result: The optimum formulation was as following:the weight percentage of Carbopol and HPMC was 60% , the weight ratio of Carbopol and HPMC was l : 3. The amlexanox buccal tablets could be obtained with good taste, smooth-surface, uniform color ,and appropriate rigidity with convenient administration. Conclusion: The preparation technology is easy and reasonable, and the quality can be controlled.
出处 《中国药师》 CAS 2011年第6期801-804,共4页 China Pharmacist
基金 武汉市科技攻关计划(编号:201 161038346)
关键词 氨来咕诺 含片 制备 正交设计 Amlexanox Buccal tablets Preparation Orthogonal design
  • 相关文献

参考文献7

二级参考文献20

  • 1吴军正 ,周威 ,王勤涛 ,王文梅 ,王宝彦 ,曹立萍 ,夏结来 ,温德升.氨来呫诺糊剂治疗复发性阿弗他繯竦牧俅惭芯?[J].实用口腔医学杂志,2005,21(4):487-491. 被引量:21
  • 2钟晓波,陈方淳,黄姣,黄孝庆.氨来呫诺口腔贴片治疗轻型复发性口腔溃疡的临床研究[J].中国药房,2006,17(6):447-449. 被引量:13
  • 3Eisen D, Lynch DP. Selecting topical and systemic agents for recurrent aphthous stomatitis. Cutis, 2001,68(3 ) :201-206.
  • 4MacPhail L. Topical and systemic therapy for recurrent aphthous stomatitis. Semin Cutan Med Surg, 1997, 16(4) :301-307.
  • 5Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med, 2000, 108(6) :487-495.
  • 6Khandwala A,VanInwegen RG,Alfano MC.5% amlexanoxoral paste,a new treatment for recurrent minor aphthous ulcers:I.Clinical demonstration of acceleration of healing and resolution of pain[J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,1997,83(2):222.
  • 7李秉奇主编.口腔粘膜病学[M].第2版.北京:人民卫生出版社,2003:52.
  • 8Eisen D,Lynch DP.Selecting topical and systemic agents for recurrent aphthous stomatitis[J].Cutis,2001,68(3):201.
  • 9Barrons RW.Treatment strategies for recurrent oral aphthous ulcers[J].Am J Health Syst Pharm,2001,58(1):41.
  • 10李秉琦,周曾同.口腔黏膜病学[M].北京:人民卫生出版社,2003:121.

共引文献33

同被引文献46

  • 1徐刚锋,张文玉.应用卡波姆971PNF制备胃内漂浮型缓释片及其体外评价[J].中国药科大学学报,2003,34(4):317-321. 被引量:15
  • 2张存彦,王成港,王春龙,陈继英,王杰.新型胶囊囊材——羟丙甲纤维素[J].中国药学杂志,2005,40(12):891-892. 被引量:12
  • 3彭海龙,刘清飞,王义明,罗国安,李宝才.卡波姆71G和羟丙基甲基纤维素在氢氯噻嗪骨架缓释片中的应用[J].中国新药杂志,2005,14(8):1010-1014. 被引量:5
  • 4中国药典[S].二部.2010.
  • 5Pygall S R,Kujawinski S. Mechanisms of drag release in citrate buffered HPMC matrices[J].International Journal of Pharmaceutics,2009.110-120.
  • 6Sanjar S, Aoki S, Boubekeur K, et al. Inhibition of PAF-induced eosinolhil accumulation in pulmonary airways of guinea pigs by anti- asthma drugs[J]. Jpn J Pharmacol, 1989, 51(2) : 167-172.
  • 7Cao SL, Ren XW, Zhang QZ,et al. In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate[ J]. lnt J Pharm, 2009, 365 (1-2) : 109-115.
  • 8Xu X, Shen Y, Wang W. Preparation and in vitro characterization of thermosensitive and mucoadhesive hydrogels for nasal delivery of phe- nylephrine hydrochloride [ J ]. Eur J Pharm Biopharm, 2014, 88 (3) : 998-1004.
  • 9Pygall SR,Kujawinski S,et al.Mechanisms of drug release in citrate buffered HPMC matrices[J].International Journal of Pharmaceutics,2009,370:110-120.
  • 10毛世瑞,周晖,毕殿洲.鼻腔给药及其影响因素[J].西北药学杂志,1997,12(6):274-276. 被引量:4

引证文献4

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部